# AlgoMeds programs Source: https://algomeds.com/programs/ AlgoMeds is independent of pharmaceutical manufacturers. Program terms change; verify eligibility, documentation and submission instructions with the official manufacturer source. AlgoMeds does not determine eligibility or improve approval odds. ## Biktarvy patient assistance [Application guide](https://algomeds.com/programs/biktarvy/) Manufacturer program: Gilead Advancing Access [Official manufacturer source](https://www.gileadadvancingaccess.com/) Source review date: 2026-07-28 The Biktarvy patient assistance program from Gilead Sciences provides medication at no cost to eligible patients who are uninsured or underinsured. Clinics apply on the patient’s behalf using the manufacturer’s enrollment form, which requires prescriber certification, the patient’s consent and signature, and proof of household income. The hardest part of a Biktarvy application is often deciding which program a patient belongs in before a form is ever started. Manufacturer assistance sits alongside ADAP, Ryan White and 340B, each with its own eligibility and its own paperwork, and putting a patient down the wrong lane wastes the scarcest resource in an HIV clinic, staff time, while the patient stays unmedicated. These are separate programs with separate criteria; the manufacturer application is only one of them. Continuity is the clinical priority rather than a convenience, because a gap in a single-tablet regimen is a treatment interruption, not an administrative inconvenience. Panels also frequently include patients who are difficult to reach by mail or landline, so the outreach channel itself is a barrier before the form is. Confidentiality compounds it: any patient contact has to reveal nothing about the patient’s care. That is exactly why the patient-facing messages carry no patient name, no medication and no clinic name. The channel that reaches a hard-to-reach patient cannot also be the thing that discloses their status. ### Application workflow considerations - Manufacturer assistance sits alongside ADAP, Ryan White and 340B, so staff have to know which lane a given patient belongs in before starting a form. - Continuity is the clinical priority. A gap in a single-tablet regimen is not an administrative inconvenience. - Panels often include patients who are hard to reach by mail or landline, so the outreach channel itself is a barrier. ### How does manufacturer assistance relate to ADAP? They are separate programs with separate eligibility. Confirm current criteria with each program directly. AlgoMeds handles the manufacturer application; it does not determine eligibility for any program. ### Do text messages to patients reveal anything about their care? No. Patient-facing text messages carry no patient name, no medication and no practice name, and patient-facing notification content is designed to omit patient names, medication names, and practice names. ## Cosentyx and Kesimpta patient assistance [Application guide](https://algomeds.com/programs/cosentyx/) Manufacturer program: Novartis Patient Assistance Foundation [Official manufacturer source](https://pap.novartis.com/) Source review date: 2026-07-28 Novartis runs patient assistance for Cosentyx and Kesimpta through a single enrollment form covering its patient assistance foundation range. It requires prescriber certification of the diagnosis, the patient’s consent and signature, and proof of household income. The form is published in English and Spanish. One document covers both, even though Cosentyx sits in dermatology and rheumatology while Kesimpta sits in neurology. Each patient needs their own enrollment and the prescriber certifies the specific drug and diagnosis, but the form itself does not change between the two clinics. English and Spanish versions exist, so a patient completes their section in the language they actually read rather than working through a translation at the counter. ### Application workflow considerations - Both are self-injected and ship to the patient, so the practice loses visibility once product leaves, a supply gap is reported by the patient, if at all. - Both are dosed monthly, which is frequent enough that an enrollment gap becomes a missed dose quickly. - Cosentyx is available in more than one route of administration for some indications, so a practice may run two workflows under one brand name. - Cosentyx indications span dermatology and rheumatology, so the prescriber attestation differs even when the drug does not. - Kesimpta patients switching from an infused therapy are moving from a workflow the practice controls to one it does not. ### Does the route of administration change which form is used? Programs sometimes use variant forms depending on how a product is administered. AlgoMeds resolves the correct current form and asks for a disambiguating detail only when the program genuinely requires one. ### How are Spanish-speaking patients handled? English and Spanish program forms are first-class in AlgoMeds, with curated clinical vocabulary rather than machine translation, so a patient completes their section in the language they actually read. ## Darzalex patient assistance [Application guide](https://algomeds.com/programs/darzalex/) Manufacturer program: Johnson & Johnson patient access resources [Official manufacturer source](https://www.jnj.com/innovativemedicine/us/how-we-work/patient-resources/patient-assistance) Source review date: 2026-07-28 The Darzalex patient assistance program from Johnson & Johnson provides medication at no cost to eligible patients who are uninsured or underinsured. Practices apply on the patient’s behalf using the manufacturer’s enrollment form, which requires prescriber certification, the patient’s consent and signature, and proof of household income. Darzalex sits inside multi-drug myeloma regimens, so a single treatment decision often triggers two or three separate manufacturer applications at once, each with its own form and its own foundation. The administrative cost is not one application. It is keeping several in step for the same patient, where demographics, prescriber NPI and income are identical across all of them but have to be entered correctly on each. Its administration frequency also changes over the course of treatment (more often at first, then less), which makes the enrollment expiry easy to lose track of against a shifting appointment pattern. Darzalex is available both as an in-office infusion and as a subcutaneous form, and where a program uses different forms for the two, being on the wrong one is a return rather than a correction. The practical approach is to anchor renewal to the enrollment date rather than the dosing schedule, and to reuse a normalized patient record across the whole regimen so the second and third applications inherit everything that has not changed instead of starting blank. ### Application workflow considerations - Myeloma regimens combine agents from several manufacturers at once, so a single treatment decision can trigger three separate assistance applications. - Administration frequency changes over the course of treatment, which makes it easy to lose track of when enrollment needs to be renewed. - Long treatment durations mean the same patient’s income documentation is re-collected repeatedly across years. ### Do combination myeloma regimens need one application or several? Several. Each manufacturer program is a separate enrollment with its own form. The practical benefit of a shared patient record is that the second and third applications reuse everything that has not changed. ### Who signs the prescriber section for an infused oncology product? The prescribing physician certifies the diagnosis and treatment plan. Some programs accept an alternative authorized signature. AlgoMeds renders signature areas as real signing targets on the actual program form and supports programs that accept either of two alternative prescriber signatures. ## Dupixent patient assistance [Application guide](https://algomeds.com/programs/dupixent/) Manufacturer program: Sanofi Patient Connection [Official manufacturer source](https://www.sanofipatientconnection.com/) Source review date: 2026-07-28 The Dupixent patient assistance program provides medication at no cost to eligible patients who are uninsured or underinsured. Practices apply on the patient’s behalf using the manufacturer’s enrollment form, which requires prescriber certification of the diagnosis, the patient’s consent and signature, and proof of household income. Dupixent is prescribed by dermatologists, allergists, pulmonologists and gastroenterologists, so a single health system can be running one program through four different clinics that never compare notes. The same manufacturer application is being filed by teams with different workflows, different familiarity and different volumes, which is why standardizing how it is filed, rather than letting each clinic invent its own process, is where larger groups find the most time. Two details drive most of its avoidable returns. Dosing differs by indication and, for younger patients, by weight, so a form that does not match the current prescription comes back for correction. And several indications are pediatric, which means a parent or guardian is frequently the person who actually signs, and that authority has to be recorded on the application rather than assumed. Getting onto the correct indication-specific form before anything is filled in (the point made above) and routing the signature to a verified representative when the patient is a minor can help a Dupixent application move forward with fewer corrections. Dupixent assistance is not one form. Sanofi issues a separate enrollment form for each approved indication, and the practice has to be on the right one before anything is filled in. A form completed for the wrong indication is a return, not a correction. This is the most common avoidable delay on a Dupixent application, and it gets more likely every time the indication list grows. - Asthma - Atopic dermatitis - Bullous pemphigoid - Chronic obstructive pulmonary disease (COPD) - Chronic rhinosinusitis with nasal polyps, and allergic fungal rhinosinusitis - Chronic spontaneous urticaria - Eosinophilic esophagitis - Prurigo nodularis ### Application workflow considerations - Dupixent is prescribed by dermatologists, allergists, pulmonologists and gastroenterologists, so a health system may be running the same program through four different workflows. - Pediatric indications mean a parent or guardian is frequently the person who signs. - Dosing differs by indication and by weight for younger patients, and a form that does not match the prescription comes back for correction. ### Does the indication change which Dupixent form is used? Programs sometimes use variant forms depending on indication or diagnosis. AlgoMeds resolves the correct current form and prompts for a disambiguating detail only when one is genuinely required. ### How is a parent or guardian handled on a pediatric application? A verified legal representative completes and signs the patient section, with their authority recorded on the application rather than assumed. ## Eliquis and Sotyktu patient assistance [Application guide](https://algomeds.com/programs/eliquis/) Manufacturer program: Bristol Myers Squibb Patient Assistance Foundation [Official manufacturer source](https://www.bmspaf.org/) Source review date: 2026-07-28 Bristol Myers Squibb runs patient assistance for Eliquis and Sotyktu through a single enrollment form covering several products in its foundation range. It requires prescriber certification, the patient’s consent and signature, and proof of household income. One document serves both, and it covers additional Bristol Myers Squibb products beyond these two, so a practice filing for one is already familiar with the form for the others. Each product is a separate enrollment for the patient even though the form is shared, and the prescriber certifies the specific drug. Eliquis volume is what makes this matter. Anticoagulation panels are large, and a practice filing constantly for Eliquis has effectively already trained for Sotyktu. ### Application workflow considerations - Volume is the defining problem on the Eliquis side: anticoagulation panels are large and the same program runs constantly, so the bottleneck is the queue rather than any individual form. - An interruption in anticoagulation carries immediate clinical risk, so a stalled application is not merely a paperwork problem. - Many Eliquis patients are older adults for whom a coverage gap is the trigger for applying, so circumstances have to be checked against the program rather than assumed. - Sotyktu is newer, so staff are less familiar with it despite the form being one they already use. The unfamiliarity is with the drug, not the document. - Sotyktu patients often reach it after topicals and at least one systemic therapy, which means prior-treatment history has to be assembled from the chart. ### Does the same Bristol Myers Squibb form cover other products too? The foundation uses one enrollment form across several products in its range, of which Eliquis and Sotyktu are two. Each product is still its own enrollment for the patient. Confirm the current product list on the official program page. ### What makes high-volume assistance programs different to run? The bottleneck stops being the individual form and becomes the queue. Pinned frequently-used programs, autofill from the record, and a tracked next action per application are what scale. ## Enbrel, Aimovig and Repatha patient assistance [Application guide](https://algomeds.com/programs/enbrel/) Manufacturer program: Amgen Safety Net Foundation [Official manufacturer source](https://www.amgensafetynetfoundation.com/) Source review date: 2026-07-28 Amgen runs patient assistance for Enbrel, Aimovig and Repatha on one application design, issued as a separate form per drug. Each requires prescriber certification, the patient’s consent and signature, and proof of household income. The forms are published in English and Spanish. These three sit in different clinics (rheumatology and dermatology for Enbrel, neurology for Aimovig, cardiology and primary care for Repatha), but the application a coordinator completes is the same shape in all three. Each drug has its own form, so an enrollment covers one product for one patient. What transfers between them is process knowledge, not a filing. For a multi-specialty group this is the unusual case where training staff once genuinely covers three separate service lines. English and Spanish versions exist for each, so a patient completes their section in the language they actually read. ### Application workflow considerations - All three are self-injected and ship to the patient, so the patient’s own section is the blocking item on essentially every application. - Repatha and Aimovig are usually run by teams without a dedicated assistance coordinator, so the work lands on whoever has time that day. - Both Repatha and Aimovig commonly require documented failure or intolerance of prior therapy, and assembling that history from the chart takes longer than filling the form. - Enbrel has been on the market long enough that the dominant workload is renewals rather than new applications, and pediatric patients need a guardian signature whose authority has to be recorded rather than assumed. - Preventive and maintenance therapies feel less urgent to patients than symptomatic ones, so the patient section stalls more often than it does in oncology. ### Can one application cover a patient on more than one Amgen product? No. Each drug has its own form and each enrollment covers one product for one patient. The applications look alike because they are built on one design, which is a training benefit rather than a filing shortcut. ### Who runs these applications in a practice without a dedicated coordinator? Usually a shared care-coordination or front-office team. A clear next-action queue is what makes that workable: nobody has to hold the whole process in their head, and the application shows explicitly whose turn it is. ## Eylea patient assistance [Application guide](https://algomeds.com/programs/eylea/) Manufacturer program: EYLEA4U Patient Assistance Program [Official manufacturer source](https://www.eylea.us/s/patient-support) Source review date: 2026-07-28 The Eylea patient assistance program from Regeneron provides medication at no cost to eligible patients who are uninsured or underinsured. Retina practices apply on the patient’s behalf using the manufacturer’s enrollment form, which requires prescriber certification, the patient’s consent and signature, and proof of household income. Eylea is injected on a short, recurring interval, so its assistance workflow runs against a repeating calendar rather than a single fill. Every lapse maps directly to a specific missed injection date, and the next one is usually only weeks away. That cadence makes renewal, not the first application, the dominant ongoing work in a retina practice, and it makes an enrollment that expires between injections an immediate clinical problem rather than a slow-building one. The patient population shapes how the paperwork actually gets done. Retina patients skew older and are frequently accompanied by a caregiver who is the person completing the form, so giving a verified legal representative a defined role, with their authority recorded rather than assumed at the desk, is often the difference between a completed application and an abandoned one. And because the product is administered in the practice, receipt and inventory tracking stay with the practice rather than a dispensing pharmacy. Keeping enrollment aligned to the injection schedule, by opening each renewal ahead of the expiry date, is what keeps the paperwork from ever being the reason an injection is deferred. ### Application workflow considerations - Injections recur on a short interval, so the assistance workflow runs against a repeating calendar rather than a single fill. A lapse maps directly to a missed injection date. - Patients skew older and are frequently accompanied by a caregiver who is the person actually completing the paperwork. - Because product is administered in the practice, receipt and inventory tracking stay with the practice rather than the pharmacy. ### Can a caregiver complete the application for a retina patient? A verified legal representative can complete and sign the patient section, with their authority recorded on the application rather than assumed informally. ### How does a practice keep enrollment aligned to an injection schedule? Renewal tasks open ahead of the recorded enrollment expiry, helping staff address paperwork before the next scheduled injection. ## Humira and Rinvoq patient assistance [Application guide](https://algomeds.com/programs/humira/) Manufacturer program: myAbbVie Assist [Official manufacturer source](https://www.abbvie.com/patients/patient-support/patient-assistance.html) Source review date: 2026-07-28 AbbVie runs patient assistance for Humira and Rinvoq on the same application design, issued as a separate form for each drug. Both require prescriber certification of the diagnosis, the patient’s consent and signature, and proof of household income. A practice that has filed one already knows the layout of the other. The two forms are separate documents, so filing for a patient on Humira does not file for a patient on Rinvoq. What carries over is familiarity, not the paperwork. Because the sections and signature points line up, staff who have learned one form are not learning a new one for the second, which matters when the second application is often for a patient switching between the two. A switch from Humira to Rinvoq is a fresh enrollment. Most of the underlying patient data has not changed; only the drug-specific parts genuinely need re-collecting. ### Application workflow considerations - Between them these two cover rheumatology, dermatology and gastroenterology, so one practice may run the same program with different diagnoses and different prescriber attestations. - Humira ships to the patient and Rinvoq is dispensed through a pharmacy, so the step that blocks an application is not the same for both. - Patients frequently arrive at Rinvoq after another therapy has failed, which means a second round of paperwork inside the same year for the same person. - Biosimilar switching has made coverage status change more often, so a patient’s circumstances have to be re-checked rather than assumed from last year. ### Is the Humira application the same as the Rinvoq application? They are separate documents built on the same design. The sections, the certifications and the signature points correspond, but each drug has its own form and each patient needs their own enrollment. Confirm current requirements on AbbVie’s official program page. ### Does switching a patient from Humira to Rinvoq mean starting the paperwork over? It is a new enrollment with its own form, but most of the underlying data is unchanged. AlgoMeds stores the patient record independently of any one program form, so only the genuinely new fields have to be collected. ## Ibrance patient assistance [Application guide](https://algomeds.com/programs/ibrance/) Manufacturer program: Pfizer RxPathways [Official manufacturer source](https://www.pfizerrxpathways.com/) Source review date: 2026-07-28 The Ibrance patient assistance program from Pfizer provides medication at no cost to eligible patients who are uninsured or underinsured. Practices apply on the patient’s behalf using the manufacturer’s enrollment form, which requires prescriber certification, the patient’s consent and signature, and proof of household income. Ibrance is dosed in cycles with planned breaks, which creates a specific failure mode: a delayed enrollment does not announce itself, it quietly pushes out the start of the next cycle. Because it is an oral oncolytic dispensed through pharmacy, the practice also loses direct line of sight once the product leaves. The signal that something went wrong is often the patient calling about a delayed refill rather than an alert in the practice’s own system. It is almost always prescribed together with endocrine therapy, so the same visit raises access questions for more than one product, and the patient may need help with each. Metastatic patients stay on treatment for a long time, so a coordinator’s Ibrance workload is dominated by renewals rather than first applications, and renewals are where re-typing the same demographics and income year after year is most wasteful. The leverage is in reuse: keep the patient record program-independent so a renewal reflects the current chart, open it ahead of the enrollment expiry, and let the cyclical dosing schedule stay a clinical concern rather than an administrative one. ### Application workflow considerations - Ibrance is dosed in cycles with planned breaks, so a delayed enrollment can silently push out the start of the next cycle. - It is prescribed together with endocrine therapy, meaning the patient may need help accessing more than one product at once. - Metastatic patients are typically on therapy for a long time, so renewals stack up across a coordinator’s panel. ### What does the practice need before starting an Ibrance assistance application? Patient demographics, insurance status, prescriber NPI and license details, the diagnosis, and the patient’s household income information. AlgoMeds pre-fills all of it from the practice record and flags what is genuinely missing. ### Can office staff complete the application without the prescriber? Staff can complete everything except the prescriber-certified section and signature. AlgoMeds scopes sections by role and routes the application to whoever holds the next action, so the prescriber is only pulled in once. ## Imbruvica patient assistance [Application guide](https://algomeds.com/programs/imbruvica/) Manufacturer program: myAbbVie Assist [Official manufacturer source](https://www.abbvie.com/patients/patient-support/patient-assistance.html) Source review date: 2026-07-28 The Imbruvica patient assistance program from AbbVie provides medication at no cost to eligible patients who are uninsured or underinsured. Practices apply on the patient’s behalf using the manufacturer’s enrollment form, which requires prescriber certification, the patient’s consent and signature, and proof of household income. Imbruvica is an oral oncolytic, which puts its application on a different track from the infused oncology programs in the same clinic. It is dispensed through specialty pharmacy, so after the manufacturer approves enrollment there is a second hand-off to the pharmacy that actually fills it, and that step sits outside the practice’s own systems and is where continuity most often breaks. An approval that never converts into a first fill looks identical to an approved patient in the chart until someone checks. Because the drug is taken continuously rather than in cycles, there is no scheduled appointment to catch a lapse: enrollment has to be tracked against its own expiry date, not against a visit. Patients are frequently older and on long-term therapy, so the same income documentation is requested again at each renewal, which makes carrying verified data forward, rather than re-collecting it, the difference between a renewal that takes minutes and one that stalls. The most reliable way to keep an Imbruvica patient supplied is to open the renewal well ahead of expiry and to treat the specialty-pharmacy confirmation as part of the application rather than the end of it. ### Application workflow considerations - Imbruvica is taken continuously rather than in cycles, so a lapse in enrollment is a lapse in therapy on an ordinary Tuesday with no appointment to catch it. - As an oral oncolytic it is dispensed through specialty pharmacy, adding a coordination path that sits outside the practice’s own systems. - Patients are frequently older and on long-term therapy, so the same income documentation gets requested year after year. ### How does oral oncology assistance differ from assistance for an infused drug? Infused products are administered in the practice and enrollment is tied to a scheduled appointment. Oral oncolytics are dispensed to the patient through a pharmacy, so the patient section and the pharmacy hand-off are on the critical path instead. ### What is the most common reason an Imbruvica application stalls? In practice, the patient portion: signature and income documentation. AlgoMeds sends the patient a single-use, short-lived signature link by text message, with no account required. ## Keytruda patient assistance [Application guide](https://algomeds.com/programs/keytruda/) Manufacturer program: Merck Patient Assistance Program [Official manufacturer source](https://www.merckhelps.com/) Source review date: 2026-07-28 The Keytruda patient assistance program from Merck provides medication at no cost to eligible patients who are uninsured or underinsured. Practices apply on the patient’s behalf using the manufacturer’s enrollment form, which requires prescriber certification of the diagnosis and treatment plan, the patient’s consent and signature, and proof of household income. The Keytruda application behaves differently from the oral oncology programs a coordinator runs alongside it. Enrollment is anchored to an infusion appointment that is already on the schedule, so the real deadline is set by the chair rather than by the form. A submission that slips by a week is a treatment date that slips with it. The prescriber section also asks for staging and treatment-plan detail that only the treating oncologist can attest, which means the form cannot be completed end to end by front-office staff the way a demographics-and-income form can. For a practice, the work is mostly sequencing. The clinical section is the part that waits on a busy physician, so it pays to get it certified first and to move the patient’s signature and income documentation in parallel rather than after it. Keytruda is also commonly one of several concurrent applications for the same patient when it is given as part of a combination regimen, which is exactly where a shared patient record earns its keep: demographics, insurance, prescriber NPI and income are entered once and reused across every form in the regimen instead of being retyped onto each. Because the product is administered and billed in the practice, the assistance workflow also has to sit alongside buy-and-bill, so receipt and inventory stay with the practice rather than a dispensing pharmacy. ### Application workflow considerations - Keytruda is given on a repeating infusion schedule, so the application competes with an appointment that is already booked. - Immuno-oncology regimens often combine agents from different manufacturers, which means two or three separate applications for the same patient in the same week. - The prescriber section asks for diagnosis and treatment-plan detail that the coordinator cannot complete alone, so the form has to move between two people before it can go anywhere. ### Who applies for the Keytruda patient assistance program, the practice or the patient? Both contribute. The practice completes the prescriber section, including diagnosis and treatment plan, and the patient completes and signs their own section along with income documentation. Neither part can be submitted without the other. ### Does a patient need to reapply for Keytruda assistance during a course of treatment? Manufacturer programs generally set an enrollment period rather than covering an entire course of therapy indefinitely. Confirm the current re-enrollment interval on Merck’s official program page, and track the expiry date rather than waiting for a notice. ## Ocrevus patient assistance [Application guide](https://algomeds.com/programs/ocrevus/) Manufacturer program: Genentech Patient Foundation [Official manufacturer source](https://www.gene.com/patients/patient-foundation) Source review date: 2026-07-28 The Ocrevus patient assistance program from Genentech provides medication at no cost to eligible patients who are uninsured or underinsured. Practices apply on the patient’s behalf using the manufacturer’s enrollment form, which requires prescriber certification of the diagnosis, the patient’s consent and signature, and proof of household income. Ocrevus is infused roughly every six months, and that long interval is the source of its particular risk: an application that stalls has a quiet failure window of months before anyone notices, and by the time the gap surfaces the next infusion may already be booked. The enrollment is effectively a hard scheduling deadline rather than a soft one, because the infusion suite reserves the chair and the drug in advance. The patient population adds a second, easily-missed friction. Many patients with multiple sclerosis have mobility or dexterity limitations that make a printed form genuinely difficult, and a form mailed to the house is often simply never returned, which reads in the chart as a non-responsive patient rather than as an inaccessible process. The way to run an Ocrevus application is to work backwards from the scheduled infusion rather than forward from the calendar, and to keep the patient’s part to something they can complete on a phone (a signature request that needs no account at all), so the barrier is a text message, not a trip to a printer and a scanner. ### Application workflow considerations - Infusions are roughly six months apart, so an application that stalls has a long, quiet failure window before anyone notices. - The infusion appointment is booked well in advance, which turns the enrollment into a hard scheduling deadline rather than a soft one. - Patients with mobility or dexterity limitations find paper forms genuinely difficult, and a mailed form is often simply not returned. ### How far ahead should a practice start an Ocrevus assistance application? Work backwards from the scheduled infusion, not from the calendar. AlgoMeds tracks each application to delivery and decision so the coordinator can see whether the timeline is holding. ### What if a patient cannot physically complete a paper form? The patient completes their portion on a phone, and a signature-only request needs no account at all: a single-use, short-lived, identity-verified link sent by text message. ## Opdivo and Yervoy patient assistance [Application guide](https://algomeds.com/programs/opdivo/) Manufacturer program: Bristol Myers Squibb Patient Assistance Foundation [Official manufacturer source](https://www.bmspaf.org/) Source review date: 2026-07-28 Bristol Myers Squibb runs patient assistance for Opdivo and Yervoy through a single enrollment form. It requires prescriber certification of the diagnosis and treatment plan, the patient’s consent and signature, and proof of household income. The two are frequently prescribed together, and each still needs its own enrollment. These two are commonly given as a combination regimen, so the same patient often needs both enrollments at once, and the form is the same document for each. That is the unusual case where one clinical decision creates two applications that are genuinely identical in structure. The duplication is in the filing, not in the learning. Because two applications for one patient run in parallel, small inconsistencies between them are easy to introduce and hard to spot on a manual review. ### Application workflow considerations - One clinical decision routinely creates two parallel applications for the same patient in the same week. - The combination course is short and front-loaded, which compresses the time available to get an application through. - Dosing intervals vary by indication, so the enrollment window a coordinator works against differs from patient to patient. - Both are administered in the practice, so the assistance workflow has to reconcile with buy-and-bill rather than a pharmacy fill. - Small inconsistencies between the two parallel forms are easy to introduce and hard to catch before submission. ### Can a practice file one application for a patient on both Opdivo and Yervoy? No. They are separate enrollments even though the form is the same document and both are Bristol Myers Squibb programs. Each requires its own completed and signed application. AlgoMeds carries the shared patient, prescriber and income data across both so the second does not repeat the first. ### What happens if the combination course finishes before the application is approved? That is a timing question for the manufacturer program, not something a software platform can promise around. Confirm retroactive handling directly with the program. What AlgoMeds does is remove the days lost to paperwork so the application is submitted sooner. ## Otezla patient assistance [Application guide](https://algomeds.com/programs/otezla/) Manufacturer program: Amgen Safety Net Foundation [Official manufacturer source](https://www.amgensafetynetfoundation.com/) Source review date: 2026-07-28 The Otezla patient assistance program from Amgen provides medication at no cost to eligible patients who are uninsured or underinsured. Practices apply on the patient’s behalf using the manufacturer’s enrollment form, which requires prescriber certification of the diagnosis, the patient’s consent and signature, and proof of household income. Otezla is frequently the first systemic therapy a patient has ever been prescribed, which changes the administrative task: the practice is often walking someone through the assistance process for the very first time. Setting expectations up front—that the practice completes the clinical portion, the patient completes and signs their own portion, and income documentation may be required—can reduce avoidable delays. It is dispensed through a pharmacy, so an approval that never converts into a first fill is invisible to the practice unless someone deliberately checks. The application can look complete while the patient still has no medication. Twice-daily oral dosing also means adherence questions and access questions get raised in the same conversation and are easily confused, so a patient who has stopped taking it because they could not afford a refill can be mistaken for one who simply stopped. Tracking each application through to delivery, and treating the first fill rather than the approval as the finish line, is what closes that gap. ### Application workflow considerations - Otezla is often the first systemic therapy a patient tries, so the practice is frequently explaining the assistance process to someone who has never been through it. - It is dispensed through a pharmacy, so an approval that never converts into a first fill is invisible to the practice unless somebody checks. - Twice-daily oral dosing means adherence questions and access questions get raised in the same conversation and confused with each other. ### What should a practice tell a patient who has never applied for assistance before? That the practice completes the clinical portion, the patient completes and signs their own portion, and income documentation is required. Setting that expectation up front can reduce avoidable delays. ### How does the practice know the patient actually got the medication? AlgoMeds tracks each application through delivery to the manufacturer and attaches acceptance or denial proof to the record, so an application that never landed is visible before it becomes a missed fill. ## Skyrizi patient assistance [Application guide](https://algomeds.com/programs/skyrizi/) Manufacturer program: myAbbVie Assist [Official manufacturer source](https://www.abbvie.com/patients/patient-support/patient-assistance.html) Source review date: 2026-07-28 The Skyrizi patient assistance program from AbbVie provides medication at no cost to eligible patients who are uninsured or underinsured. Practices apply on the patient’s behalf using the manufacturer’s enrollment form, which requires prescriber certification of the diagnosis, the patient’s consent and signature, and proof of household income. Skyrizi is not one workflow. In dermatology it is a straightforward self-injected maintenance biologic; in some gastrointestinal settings it begins with an infused induction phase before moving to self-injection, so the same brand name covers two genuinely different administration patterns inside one practice. Where the program issues variant forms by indication, being on the dermatology form for a Crohn’s patient is a rejection, not a fixable slip. Maintenance dosing is infrequent, which is the quiet risk: an enrollment that lapses between doses can go unnoticed for months, because there is no monthly fill to make the gap visible. And because the product ships to the patient, an address that is out of date on the chart silently stops delivery without anyone in the practice seeing an error. The two things that keep a Skyrizi application healthy are resolving the correct current form for the specific indication before anything is filled in, and tracking the enrollment against its expiry date rather than against a dosing interval that may be a quarter apart, so the renewal opens before the next dose is due, not after a patient reports they have run out. ### Application workflow considerations - Skyrizi uses different dosing paths for dermatologic and gastrointestinal indications, including an infused induction phase in some GI settings, so the workflow is not the same in every practice. - Maintenance dosing is infrequent, which means a lapsed enrollment can go unnoticed for months. - The product ships to the patient, so an out-of-date address on the chart quietly stops delivery. ### Is the Skyrizi application different for a psoriasis patient and a Crohn’s patient? The prescriber section is diagnosis-specific and some programs use variant forms by indication. AlgoMeds resolves the correct current form and prompts for a disambiguating detail only when the program actually needs one. ### How do practices keep track of infrequent maintenance dosing? Renewal windows are tracked against the enrollment expiry rather than the dosing interval, and renewals open ahead of expiry so therapy does not lapse between doses. ## Stelara patient assistance [Application guide](https://algomeds.com/programs/stelara/) Manufacturer program: Johnson & Johnson patient access resources [Official manufacturer source](https://www.jnj.com/innovativemedicine/us/how-we-work/patient-resources/patient-assistance) Source review date: 2026-07-28 The Stelara patient assistance program from Johnson & Johnson provides medication at no cost to eligible patients who are uninsured or underinsured. Practices apply on the patient’s behalf using the manufacturer’s enrollment form, which requires prescriber certification of the diagnosis, the patient’s consent and signature, and proof of household income. Stelara’s inflammatory-bowel-disease patients typically start with an infused induction dose in a clinical setting before moving to self-injection at home, so one enrollment can span two administration workflows the practice tracks differently. That transition is where visibility is most often lost: the induction dose is something the practice administers and sees, and the maintenance doses that follow are shipped to the patient and are not. Maintenance dosing is infrequent, which makes a lapsed enrollment easy to miss between visits, and biosimilar availability has changed coverage patterns enough that a patient’s circumstances genuinely need re-checking each year rather than carrying over from the last application. Because indications span gastroenterology, dermatology and rheumatology, the prescriber attestation differs even when the drug does not, and some programs issue an indication-specific form. The reliable pattern is to resolve the correct current form for the drug and indication rather than reusing last year’s, to track enrollment against its expiry rather than the months-apart dosing schedule, and to re-confirm coverage status at renewal instead of assuming it held. ### Application workflow considerations - Inflammatory bowel disease patients typically start with an infused induction dose given in a clinical setting before moving to self-injection, so one enrollment spans two different administration workflows. - Maintenance dosing is infrequent, which makes a lapsed enrollment easy to miss between visits. - Biosimilar availability has changed coverage patterns, so a patient’s circumstances need re-checking rather than carrying over from last year. ### Does induction dosing need a separate application from maintenance? Program structures vary and can differ by indication. Confirm on the official Johnson & Johnson program page. AlgoMeds resolves the correct current form for the drug and indication rather than leaving staff to guess. ### How does a practice avoid a lapse when doses are months apart? Renewals are tracked against the enrollment expiry date and open ahead of it, independently of the dosing interval. ## Sunlenca patient assistance [Application guide](https://algomeds.com/programs/sunlenca/) Manufacturer program: Gilead Advancing Access [Official manufacturer source](https://www.gileadadvancingaccess.com/) Source review date: 2026-07-28 The Sunlenca patient assistance program from Gilead Sciences provides medication at no cost to eligible patients who are uninsured or underinsured. Clinics apply on the patient’s behalf using the manufacturer’s enrollment form, which requires prescriber certification, the patient’s consent and signature, and proof of household income. Sunlenca is administered on an unusual schedule that its application has to accommodate: treatment begins with an oral and injectable initiation phase before moving to injections given months apart, so a single enrollment covers two different administration patterns rather than one. The initiation phase is dense and the maintenance phase is sparse, and the paperwork has to hold across both. The long dosing interval is the quiet risk: an enrollment gap can go unnoticed until the next scheduled visit, which may be months away, so renewal has to be tracked against the enrollment expiry date rather than the appointment calendar. The stakes are higher than for a first-line regimen: Sunlenca is used in multidrug-resistant HIV, so its patients have generally exhausted other options and the cost of any interruption is correspondingly greater. Because the injections are given in the clinic, receipt of the product stays with the practice rather than a pharmacy, which means tracking each application through to delivery (with acceptance or denial attached to the record) is what prevents a missed shipment from becoming a missed dose. ### Application workflow considerations - Treatment begins with an oral and injectable initiation phase before moving to long-interval injections, so a single enrollment covers two different administration patterns. - Long dosing intervals mean an enrollment gap can go unnoticed until the next scheduled visit, months later. - Patients on this therapy have already exhausted other options, which raises the cost of any interruption. ### How does a long dosing interval change the renewal workflow? Renewal has to be tracked against the enrollment expiry date rather than the appointment calendar. AlgoMeds opens renewals ahead of expiry independently of the dosing interval. ### Who tracks product that is delivered to the clinic? Applications for office-administered products are tracked to delivery, with acceptance or denial proof attached to the application record. ## Trelegy Ellipta, Nucala and Benlysta patient assistance [Application guide](https://algomeds.com/programs/trelegy/) Manufacturer program: GSK Patient Assistance Program [Official manufacturer source](https://gskforyou.com/) Source review date: 2026-07-28 GSK publishes separate patient assistance enrollment forms for Trelegy Ellipta, Nucala and Benlysta. The products are supported through different GSK program routes, so practices should select the product-specific form and confirm its current requirements before collecting signatures or documents. These products do not use one interchangeable enrollment document. GSK lists Trelegy under its general pharmaceutical patient assistance program, while Nucala and Benlysta have their own branded support-program forms. The forms still collect many of the same categories of patient, insurance, prescriber and prescription information. Reusing verified practice data can reduce duplicate entry, but staff must use the current product-specific route. That distinction matters in pulmonology practices working with both Trelegy and Nucala: familiarity with one application does not make it valid for the other. ### Application workflow considerations - Maintenance inhalers are the highest-volume assistance category most pulmonology and primary care practices touch, hundreds of applications, not dozens. - The value per Trelegy application is lower than a biologic, so the paperwork burden per dollar of benefit is much higher and staff time is the binding constraint. - Device and strength details have to match the prescription exactly, and small mismatches generate returns. - Nucala and Benlysta can each be given in the office or self-administered at home depending on the patient, so one program spans two workflows inside the same practice. - Eligibility for the therapies themselves often depends on clinical detail (eosinophil counts, exacerbation history, disease activity) that has to be pulled before the form can be certified. ### Is patient assistance worth the staff time for a maintenance inhaler? That decision depends on the patient's circumstances and the practice workflow. Reusing verified patient and prescriber information can reduce repetitive entry, but staff should use the current GSK Trelegy patient assistance form. ### Does it matter whether the patient self-administers or comes into the office? Operationally, yes. It changes who receives product and how a gap becomes visible. Trelegy, Nucala and Benlysta use product-specific program routes, so confirm both the current form and its delivery instructions with GSK. ## Trikafta patient assistance [Application guide](https://algomeds.com/programs/trikafta/) Manufacturer program: Vertex GPS: Guidance & Patient Support [Official manufacturer source](https://www.vertexgps.com/) Source review date: 2026-07-28 The Trikafta patient assistance program from Vertex Pharmaceuticals provides medication at no cost to eligible patients who are uninsured or underinsured. Care centers apply on the patient’s behalf using the manufacturer’s enrollment form, which requires prescriber certification including genotype, the patient’s consent and signature, and proof of household income. Trikafta prescribing depends on the patient's CFTR variant, so the current genetic test result must be available to the prescriber before the application can be certified. The official label says an FDA-cleared CF genetic test should be used when genotype is unknown. Practices should confirm whether the current support-program form requires the result itself as an attachment rather than assuming that it does. Cystic fibrosis care is delivered by a multidisciplinary team at a care center, which means the person who starts an application is almost never the person who finishes it. The form crosses a nurse, a pharmacist, a social worker and a physician before it is complete. Many patients are minors, so a parent or guardian signs and that authority has to be recorded rather than assumed. Both realities point the same way: sections scoped by role, with each application explicitly routed to whoever holds the next action and a full audit trail of who did what, are what keep a document moving through a team instead of stalling in a shared inbox, and what let a genotype result attached once be reused at every renewal rather than hunted for again. ### Application workflow considerations - Eligibility for the therapy depends on the patient's CFTR variant, so the current genetic test result must be available to the prescriber before the application can be certified. - Many patients are minors, which means a parent or guardian signs and that authority has to be recorded. - Care is delivered by a multidisciplinary team, so the person who starts the application is almost never the person who finishes it. ### Why does genotype matter on a cystic fibrosis assistance application? CFTR modulator therapy is prescribed based on the patient's variant. The current result must be available to the prescriber, but the practice should confirm the current support-program attachment requirements before submitting. ### How does a multidisciplinary team share one application? Sections are scoped by role (prescriber, staff, patient, representative) and the application is explicitly routed to whoever holds the next action, with a full audit trail. ## Trulicity, Taltz and Verzenio patient assistance [Application guide](https://algomeds.com/programs/trulicity/) Manufacturer program: Lilly Cares Foundation Patient Assistance Program [Official manufacturer source](https://www.lillycares.com/) Source review date: 2026-07-28 Eli Lilly runs patient assistance for Trulicity, Taltz and Verzenio through a single enrollment form covering the Lilly product range. It requires prescriber certification, the patient’s consent and signature, and proof of household income. The form is published in English and Spanish. This is one document, not three lookalikes. The same enrollment form is used whether the patient is on a diabetes therapy, a dermatology biologic or an oral oncolytic. Each patient still needs their own enrollment, and the prescriber still certifies the specific drug and diagnosis. What does not change is the form itself. For a multi-specialty group that is a real operational saving: endocrinology, dermatology and oncology are working from the same paperwork rather than three separate ones. It also means a staff member who files these regularly for one service line can cover for another without relearning anything. ### Application workflow considerations - The three drugs sit in completely different clinics, so the practice often does not realize it is running one program three times. - Diabetes panels are large and applications repetitive, so the cost is aggregate across the panel rather than visible on any single form. - Verzenio is adjuvant therapy running for years, which makes renewal, not the first application, the dominant ongoing workload. - Taltz patients frequently arrive after failing a different biologic, meaning a second round of paperwork within the same year. - Dose adjustments are common on Verzenio, and a form completed before an adjustment can be out of date by the time it is signed. ### Does one Lilly form cover a patient taking two Lilly products? The enrollment form is shared across the product range, but each product is its own enrollment for that patient and the prescriber certifies each specifically. Confirm current requirements on Eli Lilly’s official program page before telling a patient anything. ### Our endocrinology and oncology teams both file these. Should they work the same way? They are completing the same document, so yes, the process can be standardized even though the clinics are unrelated. In practice most groups discover this only after running the two separately for a year. ## Xarelto and Invega patient assistance [Application guide](https://algomeds.com/programs/xarelto/) Manufacturer program: Johnson & Johnson patient access resources [Official manufacturer source](https://www.jnj.com/innovativemedicine/us/how-we-work/patient-resources/patient-assistance) Source review date: 2026-07-28 Johnson & Johnson runs patient assistance for Xarelto and Invega through a single enrollment form covering its patient assistance foundation range. It requires prescriber certification, the patient’s consent and signature, and proof of household income. One document covers both, despite the two drugs having almost nothing else in common: an oral anticoagulant prescribed across cardiology and primary care, and a long-acting injectable antipsychotic given in the clinic. Each patient needs their own enrollment and the prescriber certifies the specific product, but the form a coordinator opens is the same one. The practical consequence is that a health system running both is running one paperwork process, not two, and can staff it that way. ### Application workflow considerations - The two drugs are administered in opposite ways (one dispensed to the patient, one given in the clinic on a fixed interval), so the same form sits inside two very different workflows. - Anticoagulants are prescribed across cardiology, primary care and post-surgical follow-up, so no single team owns the assistance workflow. - For Invega, a missed enrollment window maps to a specific appointment and a specific missed dose rather than a gradual gap. - Invega patients frequently have a legal representative or case manager acting for them, and that authority needs a real path rather than a workaround. - The patients most likely to need assistance for either drug are often the hardest to reach for a signature. ### Why would an anticoagulant and a long-acting injectable use the same application? Because the form belongs to the manufacturer’s patient assistance foundation rather than to a single product. The foundation assesses the patient, so one enrollment form serves the range. Confirm current requirements on the official program page. ### How is a legal representative handled on the application? A verified legal representative has a defined role in the form, with identity verified before anything is disclosed and their authority recorded on the application rather than assumed informally. All brand names are trademarks of their respective owners. AlgoMeds does not host or mirror manufacturer forms.